Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.
about
Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendationsLong-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequencesMedical treatments for endometriosis-associated pelvic painSelective progesterone receptor modulators: an updateBiomarkers in reproductive medicine: the promise, and can it be fulfilled?Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroidsCDB-4124 does not cause apoptosis in cultured fibroid cells.Tracking progesterone receptor-mediated actions in breast cancerRole of nuclear progesterone receptor isoforms in uterine pathophysiology.Innovations in classical hormonal targets for endometriosis.The state-of-the-art of emergency contraception with the cutting edge drug.Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone.Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery.Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advancesUterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil.Ulipristal acetate as an emergency contraceptive agent.Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.Experimental treatments of endometriosis.Uterine fibroids - what's new?
P2860
Q24567733-EB039D83-4554-4801-A648-4015AC4BBF22Q26751927-F1DDA465-EEDA-461F-86A2-A2929B07CECBQ26991844-CFA229BD-6483-48A3-BF56-1CC64B60992AQ28239255-04808FE2-E7EB-42D0-A246-0BE65C3D79C2Q28488305-0A29CCCF-5562-4059-9ADA-50763C104AD5Q33598604-595383C7-1C17-4B78-8B5A-930A9686248EQ33851065-E1695167-F179-4B02-A1F3-E058AD3FF98EQ34388848-AD531D92-80E3-4ED5-B46E-814282CA834EQ34448400-ED028397-D02F-4C87-B84D-B383FF38EE22Q34504377-E3A32B8E-9F8C-47AE-8876-5B654745E2CEQ34631343-5A6E569E-490A-48C9-9F10-A2EB5EBB06EDQ35054401-4302A9DA-8B0E-47C4-BBFE-EDD0C9BFF9D8Q35566515-7209D962-4103-45B2-8AF7-D25D4DED63CEQ35846666-59327BD9-33E6-449E-AF8C-E172B6D06240Q36198889-CC4A4638-AA90-497D-A49F-8C39D636253FQ37349144-39710E17-2C44-4179-8C69-A37FEA905E5EQ38024429-911DCB2C-D659-486C-9AE9-90C838179E53Q38569796-09ABFA63-60E8-432E-A3A9-788AA2092305Q38575273-84B3EB97-5808-4980-B2ED-54459C0F88C5Q47135445-3AE511CB-4BAF-4C86-AAE2-5E7D5678CF42
P2860
Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Endometrial changes from short ...... ogesterone receptor modulator.
@en
Endometrial changes from short ...... ogesterone receptor modulator.
@nl
type
label
Endometrial changes from short ...... ogesterone receptor modulator.
@en
Endometrial changes from short ...... ogesterone receptor modulator.
@nl
prefLabel
Endometrial changes from short ...... ogesterone receptor modulator.
@en
Endometrial changes from short ...... ogesterone receptor modulator.
@nl
P2093
P2860
P1433
P1476
Endometrial changes from short ...... ogesterone receptor modulator.
@en
P2093
George L Mutter
Olga B Ioffe
Richard J Zaino
P2860
P2888
P304
P356
10.1038/MODPATHOL.2008.204
P577
2009-01-09T00:00:00Z